Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics granted 61,365 restricted stock units and options to purchase 19,425 shares to eight newly hired non-executive employees, effective September 1, 2026. The awards were made under the company's 2025 Inducement Equity Plan as a material inducement to employment, per Nasdaq Listing Rule 5635(c)(4), with options priced at $7.07 — the August 31, 2026 closing price. Vesting follows a standard four-year schedule with a one-year cliff.
Key figures
- Rsus granted
- 61365
- New employees
- 8
- Option shares
- 19425
- Grant effective date
- 2026-09-01
- Option exercise price usd
- 7.07
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.